| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks | CEO and President
1 company
Alan Joslyn last filed a Form 4 in February 2021, as See Remarks at OGEN. Alan Joslyn's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 66,667 shares of OGEN. Net of sales, the OGEN filings show accumulation of 66,667 shares.
Alan Joslyn has 8 Form 4 filings on record from June 2016 to February 2021, all as CEO and President at Oragenics (OGEN), 2016–2021.
The 12 reported transactions were 7 option or other derivative awards, 3 open-market purchases, 1 other transaction and 1 stock award.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
Shares as reported in the last Form 4 for each company; the most recent is from February 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 25, 2019 | OGEN Oragenics Inc | See Remarks | Buy | 66,667 | $0.00 | - | New |